Botensilimab
Botensilimab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Colorectal Adenocarcinoma、Stage II Colorectal Cancer AJCC v8、Stage III Colorectal Cancer AJCC v8、Advanced Colon Adenocarcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
18 项
全球在招研究
2 项
已进入 III/IV 期
4 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- National Cancer Institute (NCI)
- City of Hope Medical Center
- Weill Medical College of Cornell University
- The Netherlands Cancer Institute
- University of Southern California
- Gruppo Oncologico del Nord-Ovest
- Dana-Farber Cancer Institute
- Northwell Health
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、荷兰、意大利、法国
正在招募患者的 Botensilimab 研究
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
II 期招募中美国NCT07595874Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
II 期招募中美国NCT06300463Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations
II 期 / III 期招募中荷兰NCT06279130Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
I 期招募中美国NCT06336902Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
II 期招募中意大利NCT05845450RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
II 期招募中美国NCT07735624Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
早期 I 期招募中美国NCT07193862Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
II 期招募中美国NCT07516366KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
I 期招募中美国NCT06411691Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
早期 I 期招募中美国NCT07128355Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
III 期招募中法国NCT06346197A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
II 期招募中美国NCT06843434The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
II 期招募中美国NCT06843551Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
II 期招募中美国NCT07551596FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
II 期招募中美国NCT06780787A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
II 期招募中美国NCT07227636Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
II 期招募中美国NCT06589440BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases
II 期招募中美国NCT07550088
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。